In a patient with PDL1+ TNBC who has had an excellent response to sacituzumab govitecan + pembrolizumab, would you ever stop the SG and continue the pembro alone?

In ASCENT-04, patients received treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death. Pembrolizumab was administered for a maximum of 35 cycles, which is approximately two years. The strategy of discontinuing SG and continuing pembrolizumab as maintenance thera...

Most de novo patients with met TNBC would get SG/pembro if their PD-L1 CPS was > 10. We do not have enough data on what happens if a patient relapses after a KEYNOTE-522-like regimen within a year, so this is an area of active interest. Obviously, if there were a contraindication to checkpoint inhib...